Sökning: onr:"swepub:oai:gup.ub.gu.se/302241" >
Virtual and in Vitr...
Virtual and in Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
-
Bocci, G. (författare)
-
Bradfute, S. B. (författare)
-
Ye, C. (författare)
-
visa fler...
-
Garcia, M. J. (författare)
-
Parvathareddy, J. (författare)
-
Reichard, W. (författare)
-
Surendranathan, S. (författare)
-
Bansal, S. (författare)
-
Bologa, C. G. (författare)
-
Perkins, D. J. (författare)
-
Jonsson, C. B. (författare)
-
Sklar, L. A. (författare)
-
- Oprea, Tudor I (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
-
visa färre...
-
(creator_code:org_t)
- 2020-10-14
- 2020
- Engelska.
-
Ingår i: ACS Pharmacology and Translational Science. - : American Chemical Society (ACS). - 2575-9108. ; 3:6, s. 1278-1292
- Relaterad länk:
-
https://www.ncbi.nlm...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The urgent need for a cure for early phase COVID-19 infected patients critically underlines drug repositioning strategies able to efficiently identify new and reliable treatments by merging computational, experimental, and pharmacokinetic expertise. Here we report new potential therapeutics for COVID-19 identified with a combined virtual and experimental screening strategy and selected among already approved drugs. We used hydroxychloroquine (HCQ), one of the most studied drugs in current clinical trials, as a reference template to screen for structural similarity against a library of almost 4000 approved drugs. The top-ranked drugs, based on structural similarity to HCQ, were selected for in vitro antiviral assessment. Among the selected drugs, both zuclopenthixol and nebivolol efficiently block SARS-CoV-2 infection with EC50 values in the low micromolar range, as confirmed by independent experiments. The anti-SARS-CoV-2 potential of ambroxol, amodiaquine, and its active metabolite (N-monodesethyl amodiaquine) is also discussed. In trying to understand the "hydroxychloroquine"mechanism of action, both pKa and the HCQ aromatic core may play a role. Further, we show that the amodiaquine metabolite and, to a lesser extent, zuclopenthixol and nebivolol are active in a SARS-CoV-2 titer reduction assay. Given the need for improved efficacy and safety, we propose zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection and discuss their potential use as adjuvant to the current (i.e., remdesivir and favipiravir) COVID-19 therapeutics. © 2020 American Chemical Society. All rights reserved.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- amodiaquine
- COVID-19
- drug repositioning
- drug repurposing
- nebivolol
- virtual screening
- zuclopenthixol
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bocci, G.
-
Bradfute, S. B.
-
Ye, C.
-
Garcia, M. J.
-
Parvathareddy, J ...
-
Reichard, W.
-
visa fler...
-
Surendranathan, ...
-
Bansal, S.
-
Bologa, C. G.
-
Perkins, D. J.
-
Jonsson, C. B.
-
Sklar, L. A.
-
Oprea, Tudor I
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reumatologi och ...
- Artiklar i publikationen
-
ACS Pharmacology ...
- Av lärosätet
-
Göteborgs universitet